Weekly
What Meta’s ad rules catch: week of 2 November 2026
Every line below was in a supplement ad running on Meta when we read it. Each one meets a rule that Meta’s health-claims review, the FTC or the FDA acts on.
The week in numbers
We read 170 supplement ads on 30 and 31 October and 1 November, one from each of 170 brands.
- Red: 64. Wording a regulator or a platform acts on.
- Yellow: 58. Every other finding, less likely to be acted on.
- Green: 48. Nothing to flag.
The three rules met most often, across the Red and Yellow lines:
- FDA: a line that promises relief from a disease or a symptom. 31 ads.
- FTC: proof words such as “clinically proven”, “the only” or “#1”. 27 ads.
- Meta: a line that tells or asks the viewer about their own condition. 19 ads.
Of the 122 Red and Yellow lines, 54 met an FDA rule, 37 an FTC rule and 31 a Meta rule.
Eight lines, all Red
Quotes are shortened. Brand names, product names and ad identifiers are left out.
Red
1. Easing a symptom
| The line | “…can help ease joint pain and stiffness” |
| Rule | FDA, disease or symptom claims. |
| Why | Easing joint pain is relief from a symptom, which the FDA reads as a drug claim a supplement can’t make. |
| Safer | “Helps support healthy joints and flexibility.” |
Red
2. Fixing a number tied to a disease
| The line | “Your blood sugar will be balanced…” |
| Rule | FDA, disease or symptom claims. |
| Why | A promise to fix a body level tied to a disease, here blood sugar, reads as a disease claim to the FDA. |
| Safer | “Helps maintain blood sugar levels already within the normal range.” |
Red
3. Next to a prescription drug
| The line | an ad for a prostate supplement that tells the viewer no prescription drug is hidden in it. |
| Rule | FDA, comparison with a prescription drug. Meta’s health-claims review flags it too. |
| Why | The line sets the product beside a prescription drug, and the FDA reads that kind of comparison as a disease claim. |
| Safer | “A daily supplement to support healthy prostate function.” |
Red
4. Pitched to people on a drug
| The line | a headline offering support to “GLP-1 users”. |
| Rule | FDA, comparison with a prescription drug. Meta’s health-claims review flags it too. |
| Why | Pitching a supplement to people taking a prescription drug sets it beside that drug, and the FDA reads that kind of comparison as a disease claim. |
| Safer | “Essential Daily Nutritional Support” |
Red
5. A question about the viewer’s body
| The line | a question that asks the viewer about several digestive symptoms at once. |
| Rule | Meta, the personal-attributes rule. |
| Why | The line asks the viewer about their own body, and Meta’s rule bars an ad that tells or asks the viewer about their own condition. |
| Safer | “Looking for everyday support for digestion and regularity?” |
Red
6. A weight-loss goal
| The line | “…boost your metabolism and support your weight loss goals” |
| Rule | Meta, health-and-wellness standards. |
| Why | Meta’s standards reject weight-loss promises, and this line ties the product to the buyer’s weight-loss goals. |
| Safer | “A delicious superfruit drink to support a healthy metabolism.” |
Red
7. A joke about a body part
| The line | a before-and-after joke about the shape of a body part, ahead of summer. |
| Rule | Meta, health-and-wellness standards. |
| Why | The joke makes a body part the problem to fix, and Meta’s standards bar an ad that picks on a body part or appearance. |
| Safer | “Ready to feel great in your favorite summer looks?” |
Red
8. A result with a deadline
| The line | “Natural Relief in Weeks” |
| Rule | FTC, a result by a deadline. |
| Why | “In weeks” puts a time on the result, and the FTC reads a deadline as a promise the brand has to prove for a typical customer. |
| Safer | “Natural support for everyday comfort.” |
Want your own page read the same way? Put your website in the preview at merchient.com.
For the ads we read across all our sweeps, by category and by how long they had been running, see the supplement ad index for November 2026.
Risk review, not legal advice.
All issues · Back to the home page